A potent antimitotic compound
Related Products
Labeled Version(s)
44386Monomethyl Auristatin E-d8
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Monomethyl Auristatin E

Item No. 16267

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
CAS Number
474645-27-7
Synonyms
  • Brentuximab Vedotin
  • MMAE
Molecular Formula
C39H67N5O7
Formula Weight
718.0
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMSO: 5 mg/mlEthanol: 25 mg/mlPBS (pH 7.2): 0.5 mg/ml
SMILES
CC(C)[C@H](NC)C(N[C@H](C(N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)=O)C(C)C)=O
InChi Code
InChI=1S/C39H67N5O7/c1-13-25(6)34(43(10)39(49)33(24(4)5)42-38(48)32(40-9)23(2)3)30(50-11)22-31(45)44-21-17-20-29(44)36(51-12)26(7)37(47)41-27(8)35(46)28-18-15-14-16-19-28/h14-16,18-19,23-27,29-30,32-36,40,46H,13,17,20-22H2,1-12H3,(H,41,47)(H,42,48)/t
InChi Key
DASWEROEPLKSEI-UIJRFTGLSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $90

    Add

    1 mg

    $168

    Add

    5 mg

    $392

    Add

    10 mg

    $609

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Dolastatin 10 is a natural antimitotic and antineoplastic agent that binds to tubulin and inhibits tubulin polymerization.1 Monomethyl Auristatin E (MMAE) is a synthetic analog of dolastatin 10 that similarly inhibits tubulin polymerization and exhibits potent cytotoxicity. It is commonly conjugated with monoclonal antibodies directed at antigens specific to cancer cells for tumor-directed cytotoxicity.2,3 MMAE is typically coupled to the antibody via a protease-cleavable linker, allowing separation of the drug from the antibody following intracellular localization.3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kingston, D.G.I. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod. 72(3), 507-515 (2009).

    2. Francisco, J.A., Cerveny, C.G., Meyer, D.L., et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4), 1458-1465 (2003).

    3. Tse, K.F., Jeffers, M., Pollack, V.A., et al. CR011, a fully human monoclonal antibody-auristatin E conjugate for the treatment of melanoma. Clin. Cancer Res. 12(4), 1373-1382 (2006).

    4. van de Donk, N.W.C.J., and Dhimolea, E. Brentuximab vedotin. mAbs 4(4), 458-465 (2012).